An interventional study of Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma and Cyclocryoablation in treatment of refractory Glaucoma in Treatment of Refractory Glaucoma, sponsored by University of Health Sciences Lahore. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-29.
Sponsored by University of Health Sciences Lahore · Not applicable, Interventional, and Treatment
laucoma having bad prognosis after maximally tolerated medication,glaucoma that fails after filtering operations, neovascular glaucoma, glaucoma following vitrectomy and glaucoma secondary to uveitis etc. is collectively termed as refractory glaucoma. For such glaucoma patients, cyclodestructive procedures are often used to reduce IOP, as well as to relieve ocular and periocular pain. Recently,diode laser transscleral cyclophotocoagulation has proved to be an effective method for the treatment of refractory glaucoma and it has become a standard treatment for refractory glaucoma.(Yu, Q., Liang, Y., Ji, F. and Yuan, Z.,et al 2020. ) In previous articles, little is known about the long-term outcomes of micropulse diode laser cyclophotocoagulation and cyclocryotherapy. Discrepancies in the results of several large observational analyses have introduced further ambiguity on the role of micropulse diode laser cyclophotocoagulation and cyclocryotherapy.The mechanism of transcleral cyclophotocoagulation IOP lowering in refractory glaucoma is not well understood. In this study, we perform cyclocryoablation and micropulse diode laser cyclophotocoagulation in patients with refractory glaucoma and report the outcomes / mechanism of IOP control using this new surgical paradigm. The objective of our project is to assess the end result and outcome of the role of micropulse diode laser cyclophotocoagulation and cyclocryotherapy.We aim to evaluate the comparison between micropulse diode laser cyclophotocoagulation and cyclocryotherapy.
Only those subjects will be recruited who provide written informed consent. Patients are diagnosed on bases of tonometry, gonioscopy, ophthalmoscopy, perimetry. Patients' age, gender, type of glaucoma, number of diode laser treatment sessions, postoperative complications, number of hypotensive medications required to control IOP, and best corrected visual acuity (BCVA) will be evaluated. The criteria for success will be defined as postoperative IOP \<21 mmHg or >20% decrease in IOP with or without additional medical treatment.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's planned enrollment of 47 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →University of Health Sciences Lahore is the lead sponsor of 77 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Positive diagnosis of refractory glaucoma
Exclusion Criteria:
Procedure: Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma
Procedure: Cyclocryoablation in treatment of refractory Glaucoma
Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
Treatment of refractory Glaucoma by cyclocryoablation
postoperative complications
Hypotony, Fibrinous uveitis, Cystoid macular edema
Time frame: 1 year
Reduced IOP
Reduction in IOP to less than 21 mmHg medications required to control IOP
Time frame: 1 year
Decrease in number of hypotensive drugs
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Health Sciences Lahore